Cornwell G G, Pajak T F, McIntyre O R
Cancer Treat Rep. 1979 Mar;63(3):399-403.
Ten patients developed allergic reactions to iv melphalan (L-PAM) during therapy for multiple myeloma. The incidence of such reactions was 2.4% among 425 patients receiving iv L-PAM with or without other drugs and 3.9% among 255 patients receiving iv L-PAM alone. Only one such reaction was demonstrated in 294 patients who initially received oral L-PAM. The median day of first reaction to iv L-PAM was Day 222 (range, Days 44-909) and the median total dose prior to a reaction was 185 mg (range, 51-250 mg). Of five patients who subsequently received oral L-PAM, four developed a reaction similar to that experienced with the iv drug.
10例多发性骨髓瘤患者在静脉注射美法仑（左旋苯丙氨酸氮芥，L-PAM）治疗期间出现过敏反应。在425例接受静脉注射L-PAM（无论是否联用其他药物）的患者中，此类反应的发生率为2.4%；在255例仅接受静脉注射L-PAM的患者中，发生率为3.9%。在294例最初接受口服L-PAM的患者中，仅1例出现此类反应。静脉注射L-PAM首次出现反应的中位天数为第222天（范围为第44 - 909天），反应前的中位总剂量为185 mg（范围为51 - 250 mg）。在随后接受口服L-PAM的5例患者中，4例出现了与静脉用药类似的反应。
